AUSTIN, Texas, March 11, 2025 /PRNewswire/ — OsteoCentric Technologies, a global leader in innovative medical technologies, announced it has entered into a non-exclusive licensing agreement with Globus Medical, Inc., a leading musculoskeletal solutions company.
OsteoCentric’s clinically proven MIS Bone Preservation Tapping Technology & Instant Interlocking Thread-form is the first implant-to-bone interface capable of sustaining primary implant stability over time. OsteoCentric’s mission is to advance the orthopaedic industry beyond the traditional interfaces that damage bone during implant insertion.
OsteoCentric Technologies is driving the widespread adoption of its groundbreaking interface technology across all orthopaedic market segments, including but not limited to Total Joint Reconstruction, Trauma, Spine, SI Joint Fusion, Sports Medicine, Extremities, Veterinary, Oncology, Bone Anchored Prostheses, and Dental applications.
For more information on OsteoCentric Technologies please visit www.osteocentric.com.
Learn more about OsteoCentric at the American Academy of Orthopaedic Surgeons Annual 2025 Meeting. Booth #1739.
About OsteoCentric Technologies
OsteoCentric Technologies is leading an industry-wide, global revolution by developing innovative solutions to address the systemic issue of bone damage and compromised implant stability. The company’s mission is to improve orthopaedic medical technologies and patient care by delivering superior sustained biomechanical implant stability that enhances and accelerates the patient’s healing journey.
SOURCE OsteoCentric Technologies
